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Mutations in PATCHED (PTC), the human homolog of
the Drosophila patched gene, have been identified in
most exons of the gene in patients with the basal cell
nevus syndrome and in sporadic basal cell carcinomas.
We have screened the 23 PTC exons for mutations using
single strand conformation polymorphism analysis of
DNA from 86 basal cell nevus syndrome probands, 26
sporadic basal cell carcinomas, and seven basal cell nevus
Basal cell carcinomas (BCC) are the commonest humancancer, with an estimated 750,000 cases per year in theU.S.A. alone (Miller and Weinstock, 1994). The greatmajority of these occur on sun-exposed skin, and theirsteadily rising incidence is commonly attributed to ultravi-
olet mutagenesis accompanying increased recreational sun exposure.
BCC also occur in the context of the BCNS (nevoid basal cell
carcinoma syndrome, Gorlin Syndrome, MIM #109400), a rare
autosomal dominant disease in which patients have both developmental
(e.g., skeletal) abnormalities and postnatal tumors (e.g., BCC, which
occur in greater numbers and at an earlier age than in sporadic cases,
and medulloblastomas) (Gorlin, 1987). Positional cloning efforts in
many laboratories extending over a decade, culminated in 1996 in the
identification of heritable mutations in PTC in patients with the BCNS
and somatic mutations in PTC in sporadic BCC (Johnson et al, 1996;
Hahn et al, 1996), and subsequently in the identification of PTC gene
mutations in sporadic medulloblastomas and other cancers (Raffel et al,
1997; Xie et al, 1997; Wolter et al, 1997).
The PTC gene is the human homolog of the Drosophila segment
polarity gene ptc. It encodes a 12 transmembrane domain protein that
physically binds at least one of the three known vertebrate Hedgehog
molecules – Sonic hedgehog (Shh) – with high affinity. Current models
posit that Ptc protein inhibits the Hedgehog signaling pathway (HHSP)
through its interaction with the Smoothened (Smo) protein, which is
predicted to be a seven transmembrane protein with the configuration
of a G protein-coupled receptor. According to this model, Ptc inhibition
of Smo is relieved upon binding of Shh to Ptc (Stone et al, 1996;
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syndrome-associated basal cell carcinomas. This screen
identified mutations located in eight exons in 13 of the
basal cell nevus syndrome patients and in three of the
tumors. The most common mutations were frameshifts
resulting in premature chain termination. These results
provide further evidence for the crucial role of PTC as
a tumor suppressor in human keratinocytes. Keyword:
Hedgehog. J Invest Dermatol 110:885–888, 1998
Marigo et al, 1996) or following mutational inactivation of Ptc. Smo
signaling activates transcription of Hh targets including PTC, and there
is consistent upregulation of PTC transcription in BCC (Gailani et al,
1996b; Unden et al, 1997; Kallassy et al, 1997). BCC-like epidermal
proliferation and BCNS-like skeletal abnormalities are produced by
overexpression of Shh in murine and human epidermal keratinocytes,
and identical (presumably activating) SHH somatic mutations have
been identified in a sporadic basal cell carcinoma, a medulloblastoma,
and a breast carcinoma (Oro et al, 1997; Fan et al, 1997).
Further, mutations in SMO also can be found in BCC (Xie et al,
1998). Thus, activation of transcription of Hh targets can be effected
by mutations in any of the three components of the signaling pathway
that interact at the cell membrane – activating mutations in the proto-
oncogenes SHH and SMO or inactivating mutations in the tumor
suppressor gene PTC.
MATERIALS AND METHODS
Subjects One affected person from each of 86 unrelated BCNS kindreds was
studied. All studied patients had multiple BCC with onset in the second decade
of life in addition to at least one of the following: multiple keratocysts of the
jaw, palmar pits, or skeletal abnormalities. No patients meeting the above
criteria were excluded from the screen.
DNA isolation, amplification, and single strand conformation poly-
morphism (SSCP) analysis DNA was extracted from blood samples using
standard phenol-chloroform extraction techniques. Paraffin-embedded BCC
DNA was isolated as reported previously (Bonifas et al, 1994). All studied BCC
occurred on sun-exposed sites. The following polymorphic microsatellite repeat
loci for chromosome 9q were used to determine allelic deletions: D9S152,
D9S176, D9S180, D9S196, D9S197, D9S12, D9S119, D9S127, D9S280,
D9S287 (Bonifas et al, 1994; Xie et al, 1997).
SSCP analysis was performed using intronic primers designed to flank each
of the 23 exons of PTC (Xie et al, 1997). Forward primers were end-labeled
with γ P32, and exons were amplified by PCR. PCR was carried out using
100 ng of genomic DNA with amplification conditions as follows: denaturation
for 1 min at 95°C, annealing at 55°C for 19300, extension at 72°C for 19300
for 35 cycles. Amplification products were diluted 1:7 in stop solution, heated
to 90°C for 5 min, and then chilled on ice prior to loading 3.5 µl on a MDE
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Table I. Mutations identified in BCNS probands and sporadic BCCa
Source Exon Nucleotide changeb Consequence Protein regionc
BCNS 6 T886 del frameshift EL 1
BCNS 6 747–759 del frameshift EL 1
BCNS 7 T950 del frameshift EL 1
BCNS 8 G1144 ins frameshift EL 1
BCNS 8 T1127C phe→ pro EL 1
BCNS 8 1208 5 bp deletion ATGTG frameshift EL 1
BCNS 10 G →C Intron/exon border disrupted splice site TM 2
BCNS 14 T2132 del frameshift CL 3
SP BCCd 14 1887 del frameshift CL 3
BCNS 17 C 2798 del frameshift EL 2
BCNS 17 G2778 A premature stop EL 2
S-BCCe 17 G2778 A premature stop EL 2
BCNS 18 3104T ins frameshift TM 8
SP BCCd 19 G3196T premature stop TM 9
BCNS 19 GTG 3246 ins val insertion TM 10
SP BCCd 20 A3340T arg→ trp CL 4
BCNS 20 3364 10 bp del frameshift TM 11
aMutation analysis via direct sequencing or automated sequencing of DNA extracted from blood of BCNS probands (BCNS) or sporadic BCC (SP BCC).
bdel, deletion; ins, insertion.
cRegion of Ptc protein predicted to correspond to mutation site. EL, extracellular loop; TM, transmembrane domain 2, 8, 9, 10, or 11; CL, cytosolic Loop 3.
dAll sporadic BCC with identified PTC mutations also had loss of heterozygosity.
eBCNS-associated BCC.
gel (BMC bioproducts) at room temperature or 4°C and run at 6 W for 10–
12 h. After electrophoresis, the gels were transferred to Whatman chromotogra-
phy paper and dried for 1 h at 94°C. Autoradiography with Kodak XAR film
at room temperature allowed detection of PCR products after a 24 h exposure
(Chen et al, 1995).
DNA cloning and sequencing Exons with detectable SSCP abnormalities
were sequenced. PCR was performed under the same conditions described for
SSCP. Direct sequencing was performed on samples using Sequenase PCR
Product Sequencing Kit (Amersham Life Science). Further mutation detection
was pursued in a subset of samples by cloning purified PCR product into
plasmid vector pCR2.1 (Invitrogen) and sequencing cloned material either by
the Sequenase Sequencing kit or by automated sequencing using the ABI
Prism sequencer.
RESULTS
Of 26 sporadic BCC screened, 11 showed loss of heterozygosity at
one or more of the polymorphic markers examined in the PTC gene
region. All markers were at least 80% informative. Of these 11, three
tumors were found to have PTC gene mutations, each in a different
exon of the gene. One of these is predicted to result in an amino acid
substitution, one in a premature stop codon, and one in a frameshift.
The latter two of these identified BCC mutations cause premature
chain termination. These three mutations are not those considered to
be characteristic of UV-induced changes. Two of the mutations
occurred in exons encoding Ptc protein cytosolic loop regions and
one occurred in an exon encoding a transmembrane domain. We
found no SSCP abnormalities in DNA from the 15 tumors that lacked
loss of heterozygosity. Of the eight BCNS-associated BCC, two
showed loss of heterozygosity and one of these had identical mutations
identified in constitutional and tumor DNA. The results are summarized
in Table I.
We identified 13 PTC mutations among the DNA samples screened
from the 86 probands. These mutations were found in nine different
exons. Nine of the 13 resulted in frameshifts (Fig 1), one resulted in
an amino acid substitution, one in a premature stop codon, one in an
amino acid insertion, and one in disruption of a splicing site. The
results are summarized in Table I.
DISCUSSION
PTC gene mutations were identified in 13 of 86 BCNS probands, in
three of 26 sporadic BCC, and in one of eight BCNS-associated BCC.
Each of the BCC in which a mutation was identified had sustained
deletion of the second allele. Our data are consistent with the conclusion
that PTC acts as a classic tumor suppressor gene, requiring ‘‘two hits’’
Figure 1. Identification of frameshift mutation (G1144 ins) in proband
CO. Direct sequencing of PCR product of Exon 8 reveals a G insertion at
position 1144, resulting in a frameshift. Wild-type sequence reads CGAGTA-
TGTCTCACACATCAACTGG. Note that doublets occur distal to the base
pair deletion.
for tumorigenesis (Knudson, 1971) in at least some BCC. Sporadic
BCC require mutations of both alleles of PTC by postnatal insults
such as UV or X-ray irradiation, chemical carcinogenesis, or random
genetic alteration. In contrast, BCNS patients have greater susceptibility
to tumorigenesis: they inherit a germline mutation of one allele of
PTC and require only one postnatal genetic ‘‘hit’’ to inactivate the
remaining wild-type allele.
The three PTC mutations in sporadic BCC from UV-exposed sites
reported herein are not characteristic of UV-induced mutagenesis,
although one (a deletion of base pair 1887) occurs at a dipyrimidine
site. In contrast, 11 of 24 previously reported mutations in PTC in
sporadic BCC have been of the UV signature type (Gailani et al,
1996b; Unden et al, 1996; Hahn et al, 1996; Johnson et al, 1996;
Wolter et al, 1997). UVB-type signature mutations including C→T
and CC→TT base substitutions comprise the majority of p53 gene
mutations found in Caucasians in both BCC (65%) (Rady et al, 1992;
Moles et al, 1993; Ziegler et al, 1993; van der Riet et al, 1994; Gailani
et al, 1996a) and squamous cell carcinomas (SCC) (67%) (Brash et al,
1991; Pierceall et al, 1991; Moles et al, 1993). The lower incidence of
UVB signature mutations in PTC (11 of 27, 41%) suggests that
mutagenic events other than UV irradiation may also cause Ptc
inactivation and trigger tumorigenesis. Furthermore, this relatively low
fraction of BCC cells that have UVB induced mutations is consistent
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with epidemiologic studies that have found poor correlation between
UVB dose and incidence of BCC, unlike the better correlation between
UVB dose and the incidence of SCC (Strickland et al, 1989; Vitasa
et al, 1990).
Thirteen of the 16 mutations identified are expected to result in
protein truncation, with the most proximal site being the first extracellu-
lar loop. Approximately 75% of previously reported constitutional
mutations in BCNS patients and somatic mutations in BCC (whether
in BCNS patients or in nonaffected persons) are predicted to cause
premature protein truncation (Hahn et al, 1996; Johnson et al, 1996;
Gailani et al, 1996b; Unden et al, 1996; Chidambaram et al, 1996;
Wicking et al, 1997; Wolter et al, 1997; Lench et al, 1997). In addition,
mutations in exons 6 and 8 appear to be a common site of PTC
mutation (eight of 52 reported mutations in BCNS probands occur in
these exons). The identification of two mutations in exons encoding
the fourth cytosolic loop and the eleventh transmembrane domains in
this study provides further evidence for the importance of these
terminally located structures to Ptc protein tumor suppressor function.
The mechanism by which these and other mutations alter the function
of the human Ptc protein remains to be elucidated, but they are
consistent with the idea that loss of Ptc protein function results in
BCC tumorigenesis.
In Drosophila, Ptc functions as a critical component of the HHSP.
Hedgehog, a diffusible protein, binds to and inhibits Ptc. In the
absence of hedgehog inhibition, Ptc acts to inhibit Smo, an adjacent
transmembrane protein. In Drosophila, activated Smo signaling activates
Cubitus Interruptus, which encodes a transcription factor that is
homologous to the human Gli family proteins (Von Ohlen et al,
1997). Cubitus Interruptus activates transcription of wingless, ptc, and
decapentaplegic and represses transcription of hedgehog (Aza-Blanc et al,
1997; Von Ohlen et al, 1997).
The presence of a homologous HHSP that can result in tumorgenesis
in mammals is suggested by the recent report that overexpression of
wild-type Shh or mutant Smo in the epidermis of transgenic mice
produces BCC-like proliferations in the skin (Oro et al, 1997; Xie
et al, 1998). In addition, in vitro transformation of cell lines with an
expression vector containing a mutant SMO gene in cooperation with
an EIA-expressing construct resulted in an altered cell phenotype with
loss of contact inhibition and formation of foci of transformation (Xie
et al, 1998). Finally, in situ studies indicate that there is heightened
transcription of PTC and GLI mRNA in BCC, whereas normal
epidermis has no detectable PTC mRNA expression (Gailani et al,
1996b; Unden et al, 1997; Dahmane et al, 1997).
Although no kindred with mapping of the BCNS gene to any site
other than chromosome 9q has been reported, we like others have
identified PTC gene mutations in a rather low percentage of BCNS
families. Possible explanations for this discrepancy may include insensit-
ivity of SSCP, and indeed Hahn et al (1996) and Wicking et al (1997)
found PTC gene mutations by sequencing samples without detectable
SSCP abnormalities. In addition, SSCP temperature conditions were
varied (22°C and 4°C) for only two exons due to limitations in the
quantity of patient DNA, and this did in fact yield an additional
aberrant band (due to a T2132 del) that had not been found at room
temperature. Although only these two exons were additionally screened
at this low temperature, it could be extrapolated that had there been
sufficient patient DNA, further mutations might have been identified.
Alternate explanations for our low mutation identification rate include
possible promoter or enhancer region abnormalities, abnormal methyl-
ation, or the presence of another tumor suppressor gene in the same
chromosomal region.
Future studies will delineate the effect of mutant Ptc, Shh, and Smo
proteins on downstream HHSP components, including Gli, Wnt, and
TGF-β, the mechanism by which HHSP target gene transcription
triggers tumorigenesis, and therapeutic modes of suppressing pathway
activation.
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